EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Senti Biosciences's Enterprise Value is $28.56 Mil.
Senti Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-53.32 Mil. Therefore, Senti Biosciences's EV-to-FCF for today is -0.54.
The historical rank and industry rank for Senti Biosciences's EV-to-FCF or its related term are showing as below:
SNTI'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.02 Med: -0.17 Max: 2.65
Current: -0.54
During the past 4 years, the highest EV-to-FCF of Senti Biosciences was 2.65. The lowest was -12.02. And the median was -0.17.
SNTI's EV-to-FCF is ranked worse than 100% of 369
companies
in the Biotechnology industry
Industry Median: 8.9
vs SNTI: -0.54
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Senti Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Senti Biosciences's EV-to-FCF
For the Biotechnology subindustry, Senti Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Senti Biosciences's EV-to-FCF falls into.
Senti Biosciences's current Enterprise Value is $28.56 Mil.
Senti Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Senti Biosciences's PE Ratio for today is calculated as:
Senti Biosciences's share price for today is $0.3401.
Senti Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Senti Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Senti Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Senti Biosciences (Senti Biosciences) Business Description
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNTI has been successfully added to your 